This pharma giant beat analysts’ EPS estimates by $0.07 last quarter. It currently pays a 4.1% dividend, paid quarterly, although that may be reduced pending its upcoming Upjohn unit merger with Mylan.
Pfizer Inc. (PFE)
From Internet Wealth Builder
Last week, I introduced the concept of Cornerstone Stocks—key companies that should perform well even in the midst of a pandemic and emerge stronger on the other side. The first five were Walmart, Costco, BCE, AT&T, and Franco-Nevada.
This week, I’m adding five more to the list, including:
Pfizer Inc. is one of the world’s leading biopharmaceuticals companies and a leader in the race to develop a vaccine for the coronavirus. Last week the company announced it is aiming to have 10-20 million doses available by year-end—assuming it meets regulatory standards. Right now, it’s in the trial stage in Germany.
But the company’s portfolio goes well beyond a COVID-19 vaccine. Its business units include Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines, and Internal Medicine. Its Upjohn division focuses on off-patent and generic medicines.
The company recently released first-quarter results, in which it reaffirmed its guidance for earnings per share of US$2.82-2.92 for 2020 and says it has adequate liquidity for the foreseeable future. The stock pays a secure quarterly dividend of US$0.38.
Gordon Pape, Internet Wealth Builder, www.buildingwealth.ca, 1-888-287-8229, May 5, 2020